Neue Substanzen in der Therapie der Angina pectoris
Standard
Neue Substanzen in der Therapie der Angina pectoris. / Meinertz, T; Köster, R.
in: INTERNIST, Jahrgang 52, Nr. 7, 07.2011, S. 894-896.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Neue Substanzen in der Therapie der Angina pectoris
AU - Meinertz, T
AU - Köster, R
PY - 2011/7
Y1 - 2011/7
N2 - There is a renaissance of medical treatment of chronic angina pectoris despite of advances in interventional therapy. New drugs include nicorandil, ivabradine and ranolazine. Nicorandil dilates venous and arterial vessels via relaxation of smooth muscle cells. Since the drug has only recently been approved, the German experience is limited. Ivabradine exerts an anti-anginous effect by selective action on the sinus node with reduction of heart rate. Multiple studies have demonstrated its anti-anginal efficacy, which has also been shown if it was used as an additional therapy to classic anti-anginal treatment. Its use is reasonable as a substitute for beta-blockers or as an "add-on therapy" combined with beta-blockers, if the target heart rate for treatment of angina pectoris has not been reached. Ranolazine delays the late sodium current into the myocytes. Thereby, it improves the diastolic ventricular function and the microcirculation of the myocardium. Several large studies confirmed the anti-anginal efficacy of the drug. Currently it is used if angina pectoris still occurs under a combined treatment with different classic anti-anginal drugs.
AB - There is a renaissance of medical treatment of chronic angina pectoris despite of advances in interventional therapy. New drugs include nicorandil, ivabradine and ranolazine. Nicorandil dilates venous and arterial vessels via relaxation of smooth muscle cells. Since the drug has only recently been approved, the German experience is limited. Ivabradine exerts an anti-anginous effect by selective action on the sinus node with reduction of heart rate. Multiple studies have demonstrated its anti-anginal efficacy, which has also been shown if it was used as an additional therapy to classic anti-anginal treatment. Its use is reasonable as a substitute for beta-blockers or as an "add-on therapy" combined with beta-blockers, if the target heart rate for treatment of angina pectoris has not been reached. Ranolazine delays the late sodium current into the myocytes. Thereby, it improves the diastolic ventricular function and the microcirculation of the myocardium. Several large studies confirmed the anti-anginal efficacy of the drug. Currently it is used if angina pectoris still occurs under a combined treatment with different classic anti-anginal drugs.
KW - Acetanilides/adverse effects
KW - Angina Pectoris/drug therapy
KW - Benzazepines/adverse effects
KW - Coronary Artery Disease/drug therapy
KW - Cyclic Nucleotide-Gated Cation Channels/drug effects
KW - Double-Blind Method
KW - Drug Approval
KW - Enzyme Inhibitors/adverse effects
KW - Humans
KW - Ivabradine
KW - Nicorandil/adverse effects
KW - Piperazines/adverse effects
KW - Randomized Controlled Trials as Topic
KW - Ranolazine
KW - Vasodilator Agents/adverse effects
U2 - 10.1007/s00108-011-2854-z
DO - 10.1007/s00108-011-2854-z
M3 - SCORING: Review
C2 - 21713611
VL - 52
SP - 894
EP - 896
JO - INTERNIST
JF - INTERNIST
SN - 0020-9554
IS - 7
ER -